JAGX Latest Press Releases

-- August 5, 2026 --

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 ACCESS Newswire 9:00 AM

-- July 28, 2026 --

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog ACCESS Newswire 9:00 AM

-- July 22, 2026 --

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) ACCESS Newswire 9:00 AM

-- June 30, 2026 --

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) ACCESS Newswire 9:00 AM

-- June 26, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing Globe Newswire 8:35 AM

-- June 25, 2026 --

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend ACCESS Newswire 9:00 AM

-- June 23, 2026 --

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESS Newswire 9:00 AM

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th Globe Newswire 8:35 AM

-- June 22, 2026 --

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program ACCESS Newswire 9:00 AM

-- June 18, 2026 --

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention ACCESS Newswire 9:00 AM

-- June 12, 2026 --

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases ACCESS Newswire 9:00 AM

-- June 10, 2026 --

Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream Globe Newswire 7:00 AM

-- June 9, 2026 --

Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream Globe Newswire 7:00 AM

-- June 8, 2026 --

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders ACCESS Newswire 4:15 PM

-- May 28, 2026 --

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders ACCESS Newswire 10:00 AM

-- May 27, 2026 --

Jaguar Health Compliant with Nasdaq Bid Price Rule ACCESS Newswire 9:00 AM

-- May 20, 2026 --

Jaguar Health Reports First Quarter 2026 Financials ACCESS Newswire 4:40 PM

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference ACCESS Newswire 9:00 AM

-- May 19, 2026 --

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer ACCESS Newswire 9:05 AM

-- May 8, 2026 --

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule ACCESS Newswire 9:00 AM

-- May 6, 2026 --

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) ACCESS Newswire 9:00 AM

-- May 4, 2026 --

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health ACCESS Newswire 8:30 AM

-- April 29, 2026 --

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs ACCESS Newswire 8:30 AM

-- April 27, 2026 --

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split ACCESS Newswire 9:00 AM

-- April 24, 2026 --

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) ACCESS Newswire 8:30 AM

-- April 20, 2026 --

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders ACCESS Newswire 4:15 PM

-- April 13, 2026 --

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs ACCESS Newswire 8:30 AM

-- April 9, 2026 --

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates ACCESS Newswire 8:16 PM

-- April 8, 2026 --

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESS Newswire 8:30 AM

-- April 7, 2026 --

Jaguar Health Reports 2025 Financials ACCESS Newswire 8:30 AM

-- April 2, 2026 --

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress ACCESS Newswire 9:00 AM

-- March 18, 2026 --

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) ACCESS Newswire 9:00 AM

-- March 16, 2026 --

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression ACCESS Newswire 9:00 AM

-- March 13, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing Globe Newswire 8:35 AM

-- March 11, 2026 --

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts ACCESS Newswire 9:00 AM

-- March 10, 2026 --

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th Globe Newswire 10:21 AM

-- March 9, 2026 --

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants ACCESS Newswire 9:00 AM